Table 1.
Clinical and pathological characteristics of patients stratified by (a) the number of RLNs; (b) LNR and LODDS
| (a) | |||||||
|---|---|---|---|---|---|---|---|
| Total number of resected lymph nodes | Total | ||||||
| 1 node | 2‐3 nodes No. (%)a | 4‐5 nodes No. (%)a | 6‐15 nodes No. (%)a | 16‐30 nodes No. (%)a | ≥31 nodes No. (%)a | ||
| Age | |||||||
| Mean | 59.7 ± 0.4 | 58.8 ± 0.4 | 57.8 ± 0.4 | 57.0 ± 0.2 | 56.3 ± 0.2 | 54.9 ± 0.4 | 57.2 ± 0.1 |
| Median (range) | 59.0 (16‐91) | 59.0 (18‐90) | 57.0 (18‐96) | 56.0 (15‐92) | 56.0 (16‐90) | 54.5 (21‐88) | 57.0 (15‐96) |
| Tumor size | |||||||
| ≤1 cm | 27 (0.3%) | 23 (0.3%) | 14 (0.2%) | 77 (1.0%) | 68 (0.9%) | 15 (0.2%) | 224 (2.8%) |
| 1‐5 cm | 152 (1.9%) | 201 (2.5%) | 143 (1.8%) | 536 (6.7%) | 383 (4.8%) | 161 (2.0%) | 1576 (19.8%) |
| 5‐10 cm | 213 (2.7%) | 291 (3.6%) | 257 (3.2%) | 855 (10.7%) | 640 (8.0%) | 211 (2.6%) | 2467 (30.9%) |
| 10‐20 cm | 271 (3.4%) | 367 (4.6%) | 304 (3.8%) | 1101 (13.8%) | 779 (9.8%) | 282 (3.5%) | 3104 (38.9%) |
| >20 cm | 48 (0.6%) | 62 (0.8%) | 59 (0.7%) | 228 (2.9%) | 153 (1.9%) | 54 (0.7%) | 604 (70.6%) |
| Race | |||||||
| Caucasians | 949 (8.7%) | 1129 (10.4%) | 880 (8.1%) | 3218 (29.6%) | 2230 (20.5%) | 819 (7.5%) | 9225 (84.8%) |
| Black | 75 (0.7%) | 105 (1.0%) | 67 (0.6%) | 171 (1.6%) | 104 (1.0%) | 29 (0.3%) | 551 (5.1%) |
| African | 13 (0.1%) | 10 (0.1%) | 9 (0.1%) | 16 (0.1%) | 6 (0.1%) | 6 (0.1%) | 60 (0.6%) |
| Asiansa | 63 (0.6%) | 114 (1.0%) | 95 (0.9%) | 325 (3.0%) | 256 (2.4%) | 104 (1.0%) | 957 (8.8%) |
| Pacific islander | 4 (0.0%) | 6 (0.1%) | 4 (0.0%) | 16 (0.1%) | 15 (0.1%) | 6 (0.1%) | 51 (0.5%) |
| Othersb | 0 (0.0%) | 0 (0.0%) | 4 (0.0%) | 5 (0.0%) | 7 (0.1%) | 2 (0.0%) | 18 (0.2%) |
| Unknown | 0 (0.0%) | 2 (0.0%) | 2 (0.0%) | 4 (0.0%) | 6 (0.1%) | 2 (0.0%) | 16 (0.1%) |
| Stage of disease | |||||||
| Stage I | 185 (1.7%) | 347 (3.2%) | 328 (3.0%) | 1439 (13.2%) | 1061 (9.8%) | 343 (3.2%) | 3703 (34.0%) |
| Stage II | 102 (0.9%) | 184 (1.7%) | 160 (1.5%) | 521 (4.8%) | 360 (3.3%) | 117 (1.1%) | 1444 (13.3%) |
| Stage III | 530 (4.9%) | 546 (5.0%) | 408 (3.8%) | 1309 (12.0%) | 893 (8.2%) | 383 (3.5%) | 4069 (37.4%) |
| Stage IV | 287 (2.6%) | 289 (2.7%) | 165 (1.5%) | 486 (4.5%) | 310 (2.8%) | 125 (1.1%) | 1662 (15.3%) |
| Grade of disease | |||||||
| Grade 1 | 95 (0.9%) | 166 (1.5%) | 157 (1.4%) | 595 (5.5%) | 410 (3.8%) | 145 (1.3%) | 1568 (14.4%) |
| Grade 2 | 259 (2.4%) | 332 (3.1%) | 260 (2.4%) | 1019 (9.4%) | 696 (6.4%) | 225 (2.1%) | 2791 (25.7%) |
| Grade 3 | 750 (6.9%) | 868 (8.0%) | 644 (5.9%) | 2141 (19.7%) | 1518 (14.0%) | 598 (5.5%) | 6519 (59.9%) |
| Histology | |||||||
| Serous | 732 (6.7%) | 807 (7.4%) | 565 (5.2%) | 1828 (16.8%) | 1232 (11.3%) | 475 (4.4%) | 5639 (51.8%) |
| Clear cell | 75 (0.7%) | 115 (1.1%) | 114 (1.0%) | 456 (4.2%) | 365 (3.3%) | 125 (1.1%) | 1249 (11.5%) |
| Mucinous | 69 (0.6%) | 101 (0.9%) | 78 (0.7%) | 342 (3.1%) | 180 (1.7%) | 65 (0.6%) | 835 (7.7%) |
| Endometrioid | 205 (1.9%) | 323 (3.0%) | 275 (2.5%) | 1051 (9.7%) | 806 (7.4%) | 282 (2.6%) | 2942 (27.17%) |
| Carcinosarcoma | 12 (0.1%) | 8 (0.1%) | 13 (0.1%) | 35 (0.3%) | 28 (0.3%) | 13 (0.1%) | 109 (1.0%) |
| Undifferentiated | 11 (0.1%) | 12 (0.1%) | 16 (0.1%) | 43 (0.4%) | 14 (0.1%) | 8 (0.1%) | 104 (1.0%) |
| (b) | ||||||||
|---|---|---|---|---|---|---|---|---|
| LNR | LODDS | Total | ||||||
| 0%‐10% | 10%‐40% | 40%‐100% | LODDS<−1 | −1 ≤ LODDS<−0.5 | −0.5 ≤ LODDS<0 | LODDS≥0 | ||
| Age | ||||||||
| Mean | 56.5 ± 0.1 | 57.9 ± 0.4 | 59.7 ± 0.3 | 55.8 ± 0.2 | 57.8 ± 0.3 | 58.5 ± 0.3 | 59.8 ± 0.4 | 57.2 ± 0.1 |
| Median (range) | 56.0 (15‐96) | 58.0 (17‐89) | 60.0 (17‐91) | 55.0 (15‐96) | 58.0 (18‐90) | 58.0 (16‐91) | 59.0 (17‐91) | 57.0 (15‐96) |
| Tumor size | ||||||||
| ≤1 cm | 177 (2.2%) | 19 (0.2%) | 28 (0.4%) | 135 (1.7%) | 34 (0.4%) | 29 (0.4%) | 26 (0.3%) | 224 (2.8%) |
| 1‐5 cm | 1077 (13.5%) | 186 (2.3%) | 312 (3.9%) | 793 (9.9%) | 280 (3.5%) | 210 (2.6%) | 292 (3.7%) | 1575 (19.8%) |
| 5‐10 cm | 1691 (21.2%) | 293 (3.7%) | 481 (6.0%) | 1261 (15.8%) | 455 (5.7%) | 293 (3.7%) | 456 (5.7%) | 2465 (30.9%) |
| 10‐20 cm | 2391 (30.0%) | 289 (3.6%) | 422 (5.3%) | 1794 (22.5%) | 556 (7.0%) | 349 (4.4%) | 403 (5.0%) | 3102 (38.9%) |
| >20 cm | 508 (6.4%) | 48 (0.6%) | 48 (0.6%) | 389 (4.9%) | 102 (1.3%) | 69 (0.9%) | 44 (0.5%) | 604 (7.6%) |
| Race | ||||||||
| Caucasians | 6440 (59.3%) | 1056 (9.7%) | 1718 (15.8%) | 4715 (43.4%) | 1691 (15.6%) | 1184 (10.9%) | 1624 (14.9%) | 9214 (84.8%) |
| Black | 349 (3.2%) | 81 (0.7%) | 120 (1.1%) | 208 (1.9%) | 131 (1.2%) | 96 (0.9%) | 115 (1.1%) | 550 (5.1%) |
| African | 35 (0.3%) | 12 (0.1%) | 13 (0.1%) | 22 (0.2%) | 12 (0.1%) | 14 (0.1%) | 12 (0.1%) | 60 (0.6%) |
| Asians | 742 (6.8%) | 77 (0.7%) | 137 (1.3%) | 571 (5.3%) | 168 (1.5%) | 88 (0.8%) | 129 (1.2%) | 956 (8.8%) |
| Pacific islander | 41 (0.4%) | 3 (0.0%) | 7 (0.1%) | 35 (0.3%) | 5 (0.0%) | 4 (0.0%) | 7 (0.0%) | 51 (0.5%) |
| Others | 16 (0.1%) | 0 (0.0%) | 2 (0.0%) | 12 (0.1%) | 4 (0.0%) | 0 (0.0%) | 2 (0.0%) | 18 (0.2%) |
| Unknown | 15 (0.1%) | 0 (0.0%) | 1 (0.0%) | 12 (0.1%) | 3 (0.0%) | 0 (0.0%) | 1 (0.0%) | 16 (0.1%) |
| FIGO stage of disease | ||||||||
| Stage I | 3666 (33.7%) | 29 (0.3%) | 8 (0.1%) | 2975 (27.4%) | 525 (4.8%) | 195 (1.8%) | 8 (0.1%) | 3703 (34.1%) |
| Stage II | 1344 (12.4%) | 37 (0.3%) | 59 (0.5%) | 1015 (9.3%) | 267 (2.5%) | 101 (0.9%) | 57 (0.6%) | 1440 (13.3%) |
| Stage III | 1997 (18.4%) | 859 (7.9%) | 1208 (11.1%) | 1263 (11.6%) | 906 (8.3%) | 761 (7.0%) | 1134 (9.5%) | 4064 (37.4%) |
| Stage IV | 631 (5.8%) | 304 (2.8%) | 723 (6.7%) | 322 (3.0%) | 316 (2.9%) | 329 (3.0%) | 691 (6.4%) | 1658 (15.3%) |
| Grade of disease | ||||||||
| Grade 1 | 1424 (13.1%) | 76 (0.7%) | 67 (0.6%) | 114 (10.3%) | 272 (2.5%) | 118 (1.1%) | 63 (0.5%) | 1567 (14.4%) |
| Grade 2 | 2241 (20.6%) | 205 (1.9%) | 342 (3.1%) | 1664 (15.3%) | 497 (4.6%) | 313 (2.9%) | 314 (2.9%) | 2788 (25.7%) |
| Grade 3 | 3973 (36.6%) | 948 (8.7%) | 1589 (14.6%) | 2797 (25.7%) | 1245 (11.5%) | 955 (8.8%) | 1513 (5.2%) | 6510 (59.9%) |
| Histology | ||||||||
| Serous | 3054 (28.1%) | 930 (8.6%) | 1644 (15.1%) | 1987 (18.3%) | 1127 (10.4%) | 966 (8.8%) | 1548 (14.3%) | 5628 (51.8%) |
| Clear cell | 1066 (9.8%) | 90 (0.8%) | 93 (0.9%) | 869 (8.0%) | 192 (1.8%) | 97 (0.9%) | 91 (0.8%) | 1249 (11.5%) |
| Mucinous | 760 (7.0%) | 38 (0.3%) | 37 (0.3%) | 576 (5.3%) | 154 (1.4%) | 71 (0.7%) | 34 (0.3%) | 835 (7.7%) |
| Endometrioid | 2626 (24.1%) | 136 (1.2%) | 178 (1.6%) | 2056 (18.9%) | 490 (4.6%) | 221 (2.0%) | 173 (1.5%) | 2940 (27.1) |
| Carcinosarcoma | 75 (0.7%) | 15 (0.1%) | 19 (0.2%) | 50 (0.5%) | 27 (0.2%) | 14 (0.1%) | 18 (0.2%) | 109 (1.0%) |
| Undifferentiated | 57 (0.5%) | 20 (0.2%) | 27 (0.2%) | 37 (0.3%) | 24 (0.2%) | 17 (0.2%) | 26 (0.3%) | 104 (1.0) |
a
Asians were defined as Chinese, Japanese, Korean, Vietnamese, and Filipino.
b
Others were defined as all other race/ethnicity parameters.